1. A 16-week dose finding double blind study of KE-298, a newly developed novel DMARD, in patients with rheumatoid arthritis;Abe;Proc. XIXth ILAR Congress Rheum.,1997
2. Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298;Yasuda;Drugs Exp. Clin. Res.,1996
3. Suppressive effect of a new anti-rheumatic drug KE-298 on TNF-α-induced matrix metalloproteinase production in RA synoviocytes;Takahashi;Drugs Exp. Clin. Res.,1998
4. Mechanisms of KE-298, 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid, to suppress abnormal synovial cell functions in patients with rheumatoid arthritis;Sakane;J. Rheumatol.,1997
5. Effect of KE-298 on experimental arthritis in mice;Nagai;Pharmacology,1996